Merck Canada and MaRS Team Up to Launch Lung Cancer Innovation Challenge

Challenge aimed at improving patient outcomes by identifying solutions to reduce time between diagnosis and treatment for lung cancer patients

Merck Canada and MaRS Discovery District (MaRS) are proud to launch the Lung Cancer Innovation Challenge . The competition challenges Ontario -based innovators to identify, implement and scale solutions that can enhance an Ontario lung cancer patient's journey by seeking to reduce the length of time between diagnosis and treatment for lung cancer patients, and enable improved treatment outcomes, especially for priority patient groups such as rural and lower socioeconomic populations in Ontario . Financial prizes will be awarded to the winners of the challenge. In addition, the winners may have the opportunity to collaborate on future projects with Merck Canada. Of the four most common cancers, lung cancer, has the lowest survival rate, regardless of stage at diagnosis. 1 It is estimated that 29,800 new lung cancer cases would be diagnosed in 2020 across Canada with almost 40 per cent of those cases residing in Ontario alone. 2,3 The ability for lung cancer patients to receive initial access to primary care and the proper treatment at the right time is dependent upon a number of different factors that touch on the patient, their circle of care, and the broader health system.

"We play an important role within Canada's healthcare environment, and we are very committed to helping solve key issues which patients are facing today. Our Life Sciences sector is one of the most innovative sectors imaginable and is key to tackling some of society's biggest health challenges. Innovative partnerships and joint initiatives, like this one with MaRS, are allowing us to collaborate and to tap into some of Ontario's brightest minds in order to bring new, invaluable solutions to people facing cancer," says AnnA Van Acker , President and Managing Director of Merck Canada. "The majority of lung cancer cases are diagnosed at Stage 4 and the disease often rapidly progresses to a point where appropriate treatment is no longer an option. The Lung Cancer Innovation Challenge provides an exciting opportunity to go above and beyond and to find much needed ways to help shorten the time gap between diagnosis and treatment, thereby potentially improving patient outcomes, individually and collectively."

The challenge kicks off today, January 20 , with a virtual launch event at 11 a.m. EST featuring a panel discussion on the barriers and opportunities associated with the diagnosis and treatment of lung cancer. Panelists representing a diverse range of perspectives across the healthcare system — including patients, healthcare providers and other innovators — will share their experiences and speak to the additional challenges posed by the COVID-19 pandemic.

"Fighting lung cancer during a pandemic means reduced access to primary care, diagnosis and screening. It's also a very lonely process with tightened restrictions on visitor policies," says Alex Ryan , SVP, Partner Solutions at MaRS. "By partnering with Merck Canada, we will help foster innovative solutions that diffuse some of the COVID-19 complexities lung cancer patients encounter while strengthening and building long-term resiliency in Ontario's health care system."

"I'd like to congratulate Merck Canada and MaRS on the launch of this joint initiative," said Nina Tangri , Parliamentary Assistant to the Minister of Economic Development, Job Creation, and Trade. "Now more than ever, we need innovation and new ideas to better our healthcare system. I look forward to seeing the novel and life-changing solutions that Ontario's innovators submit to the challenge to help patients and families."

The challenge will run until March 25, 2021 , and the grand-prize winner will receive a $100,000 prize with $50,000 going to the runner-up prize winner. Winners will be announced by April 28, 2021 . Please go here for more information or to register for the launch event.

About Merck
For more than 125 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world.

About MaRS
MaRS is North America's largest urban innovation hub. A registered non-profit, MaRS supports high-growth startups and scale-ups tackling key issues in health, cleantech, fintech and other sectors. In addition, MaRS convenes all members of the tech ecosystem to drive breakthrough discoveries, grow the economy and make an impact by solving real problems for real people — in Canada and around the world.

References

_______________________________

1 Ontario Cancer Statistics 2018 — Cancer Care Ontario

2 Ontario Cancer Statistics 2018 — Cancer Care Ontario

3 Target Wait Times for Cancer Surgery in Ontario, 2016 — Cancer Care Ontario

SOURCE Merck

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/January2021/20/c1543.html

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)
Cardiol Therapeutics (TSX:CRDL)

Cardiol Therapeutics


Keep reading...Show less
Seegnal Inc. (TSXV:SEGN)

Seegnal Inc. Announces Extension of Maccabi Health Services Contract

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Corporation"), a global leader in SaaS clinical division support solutions, is pleased to announce that effective September 8, 2025, it has amended its contract with Maccabi Health Services ("Maccabi") for an additional six years and has also expanded the scope of the contract to include all of Maccabi's pharmacies and additional nurses. Maccabi is the second largest Healthcare Management Organization ("HMO") in Israel, serving over 2.6 million Israelis and is renowned for its use of technology and emphasis on patient-centered care, according to Maccabi's website here.

Pursuant to the amended agreement, Seegnal will continue to deliver its patented prescription co-pilot platform for an additional six years, to September 22, 2031, while expanding the scope to nurses and pharmacists in all of Maccabi's nationwide pharmacies. Maccabi is the first in Israel and one of the first HMOs worldwide to offer an end-to-end safety coverage throughout the patient journey, allowing complete visibility to pharmacists in the pharmacies into clinician decision while prescribing patient centric medication. The expanded contract was changed from a fixed base contract to Seegnal's current SaaS based model based on Quarterly Recurring License Fees and is expected to generate additional revenue for the Corporation.

Keep reading...Show less
Numinus Wellness Inc. Announces Third Quarter Fiscal 2025 Results

Numinus Wellness Inc. Announces Third Quarter Fiscal 2025 Results

All financial results are reported in Canadian dollars unless otherwise stated.

Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) (FSE: LR23) ("Numinus" or the "Company") a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months ended May 31, 2025 ("Q3 2025 ").

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Invion Executive Chair and CEO Thian Chew.

Invion CEO Maps Path to Peer-level Valuation as Momentum for Cancer Treatment Trials Builds

Invion (ASX:IVX) Executive Chair and CEO Thian Chew says the company sees a path to a rerate toward clinical-stage oncology peers — typically valued from AU$30 million to AU$40 million up to several hundred million — if it executes on a trio of near-term priorities: simplifying licencing, cleaning up shareholder financing structures and dialling up investor awareness.

In an interview with the Investing News Network, Chew stressed that Invion’s fundamentals are already in place: a platform therapy being tested across multiple cancers with an active clinical program, and a US Food and Drug Administration orphan drug designation potentially fast tracking approvals.

“The challenge is making sure people invest the time to understand where we're at. So if we solve all those three, even without doing any more development work, then we believe that we can get around the comparable levels of valuation, and that creates some interesting opportunities for us,” Chew said.

Keep reading...Show less
Numinus Wellness Inc. Announces Second Quarter Fiscal 2025 Results

Numinus Wellness Inc. Announces Second Quarter Fiscal 2025 Results

All financial results are reported in Canadian dollars unless otherwise stated.

Numinus Wellness Inc.  (TSX: NUMI) (OTCQB: NUMIF) (FSE: LR23) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months ended February 28, 2025 ("Q2 2025").

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

Top 5 Small-cap Pharma Stocks of 2025

Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval. However, the industry's major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected to dissipate.

The US reigns supreme in the pharma market, both in terms of drug demand and development. In 2024, 50 novel medicines were approved by the US Food and Drug Administration (FDA), compared to 55 such approvals in 2023. Last year's FDA approvals include Eli Lilly and Company's (NYSE:LLY) Alzheimer's disease treatment Kisunla.

Big pharma largely steals the show, but some small- and mid-cap NASDAQ pharma stocks have also made gains.

Keep reading...Show less

Latest Press Releases

Related News

×